Akèy › Kansè kolorektal › Arizona › Gilbert
Etid klinik pou Kansè kolorektal nan Gilbert, AZ
9 etid pou Kansè kolorektal ap chèche patisipan nan sit nan ak bò kote Gilbert (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Gilbert
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center, Gilbert
- Ironwood Cancer & Research Centers, Gilbert
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center, Gilbert
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Banner Health, Gilbert
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center, Gilbert
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center, Gilbert
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Banner Health- MD Anderson Cancer Center, Gilbert
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Banner Health, Gilbert
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Banner MD Anderson Cancer Center, Gilbert
Etid Kansè kolorektal nan lòt vil
- Houston, TX102 etid
- New York City, NY78 etid
- Nashville, TN69 etid
- Boston, MA63 etid
- Los Angeles, CA59 etid
- Arlington, VA52 etid
- St. Louis, MO50 etid
- San Antonio, TX46 etid
- Philadelphia, PA44 etid
- Grand Rapids, MI40 etid
- Baldwin Park, CA37 etid
- Chicago, IL34 etid
Lòt etid nan Gilbert
- Kansè Poumon ki pa ti selil13 etid
- Kansè nan tete10 etid
- Kansè (tout kalite)8 etid
- Kansè poumon8 etid
- Kansè vejik6 etid
- Ensifizyans kadyak6 etid
- Myelom Miltip6 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Maladi kadyovaskilè6 etid
- Kansè Metastatik6 etid
- Limfom Difize Gwo Selil B5 etid
- Limfòm Non-Hodgkin5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.